Monoacylglycerol Form of Omega-3s Improves Its Bioavailability in Humans Compared to Other Forms.

Détails

Ressource 1Télécharger: 32272659_BIB_BB13B9FF12B5.pdf (2597.26 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY 4.0
ID Serval
serval:BIB_BB13B9FF12B5
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Monoacylglycerol Form of Omega-3s Improves Its Bioavailability in Humans Compared to Other Forms.
Périodique
Nutrients
Auteur(s)
Cuenoud B., Rochat I., Gosoniu M.L., Dupuis L., Berk E., Jaudszus A., Mainz J.G., Hafen G., Beaumont M., Cruz-Hernandez C.
ISSN
2072-6643 (Electronic)
ISSN-L
2072-6643
Statut éditorial
Publié
Date de publication
07/04/2020
Peer-reviewed
Oui
Volume
12
Numéro
4
Pages
1014
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: epublish
Résumé
Numerous benefits are attributed to omega-3 fatty acids (OM3) especially in cardiovascular health. However, bioavailability and clinical efficacy depend on numerous factors, including OM3 form, food matrix effects (especially the lipid content of the diet), and metabolic capacity. Here, we show in humans that a "pre-digested" OM3-sn-1(3)-monoacylglycerol lipid structure (OM3-MAG) has a significantly greater absorption at high therapeutic doses (2.9 g/day) than the most commonly OM3-ethyl ester (3.1 g/day) form (used for the treatment of hypertriglyceridemia), and a comparable profile to other pre-digested OM3 free fatty acids (OM3-FFA) structure (3.2 g/day). Nutritional supplement doses of MAG resulted in similar increases in OM3 blood level, compared to OM3 triacylglycerols (OM3-TAG) supplements in obese subjects (1.2 g/day) under low fat diet, and in children with cystic fibrosis (1.0 g/day). These results suggest that both forms of pre-digested OM3-MAG and OM3-FFA are effectively absorbed and re-incorporated effectively into triacylglycerols inside the enterocytes, before being exported into the chylomicrons lipid transport system. The pre-digested OM3-MAG might provide a more effective therapy in severe cardiovascular conditions where high doses of OM3 are required and a low-fat diet is indicated, which limited digestive lipase activity.
Mots-clé
cystic fibrosis, fatty acid digestion, hypertriglyceridemia, lipid absorption, obesity, omega 3, omega-3 sn-1(3)-monoacylglycerol
Pubmed
Open Access
Oui
Création de la notice
25/04/2020 21:32
Dernière modification de la notice
23/01/2021 7:21
Données d'usage